Shopping Cart
- Remove All
- Your shopping cart is currently empty
Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used to study gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF), as well as dengue virus.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $647 | In Stock | |
10 mg | $987 | In Stock |
Description | Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used to study gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF), as well as dengue virus. |
In vitro | Andecaliximab increases serum IL-7 levels [ 1 ]. Andecaliximab ( 50 μg / mL ; 24 h ) reduced the phosphorylation of SMAD2 ( pSMAD2 ) in ABC cell lines [ 2 ]. |
In vivo | Improving the diversity of T cell receptor (TCR) in tumor-infiltrating T cells, andecaliximab[1]. In a human NSG mouse model of idiopathic pulmonary fibrosis, andecaliximab (20 mg/kg; intraperitoneal injection, single) exhibited an anti-fibrosis effect[2]. |
Alias | GS-5745 |
Molecular Weight | 150 kDa |
Cas No. | 1518996-49-0 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.